person with multiple sclerosis

athlete with multiple sclerosis [ multiple sclerosis athlete | MS athlete ]

Virological & Immunological Studies in Pediatric Multiple Sclerosis

multiple sclerosis ward

The income security issues we have raised with you today do not represent all of the concerns or needs of people with MS. We have focused on these issues for two reasons: secure and adequate income is the foundation for the ability of people with MS to fully exercise their rights as Canadians and to be part of mainstream economic and social life, and the recent successes of the federal government's fiscal policies have created new and important opportunities for the fairer treatment of people with disabilities.

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between D ...[+++]ecember 2013 and December 2015 and by what dates; (c) what is the cost of developing the system, broken down by costs to date; (d) how much money did the Canadian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...

Studies of MS patients by Dr. Zamboni have shown a high percentage of MS patients have a condition known as chronic cerebrospinal venous insufficiency, or CCSVI. CCSVI is a vascular abnormality which restricts the flow of blood from the brain and is potentially the cause of the high levels of iron found in the brain of MS patients.

Primarily the petition before us tries to raise awareness of access to not only medicines but also to the treatment of patients with MS. It is quite fitting that, as we end the 2003 European Year for People with Disabilities, we reflect on what we can positively do to help people with MS.